7 completed, 5 terminated, 1 withdrawn. 8 Phase 2, 6 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Terminated 2, Withdrawn 1 |
| Phase 1 | 6 | Completed 3, Terminated 3 |
| Phase 3 | 1 | Terminated 1 |
Follow Imprime PGG: new trials by email Literature Review of Imprime PGG trials Research Report on Imprime PGG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma odetiglucan, CDX-1140 - Metastatic Pancreatic Adenocarcinoma | Phase 1 | Terminated | HiberCell, Inc. | 5 | 2022-12-15 | 2024-04-10 |
| Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) Imprime PGG, Pembrolizumab - Malignant Neoplasm of Breast | Phase 2 | Completed | HiberCell, Inc. | 26 | 2021-11-09 | 2023-06-22 |
| Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma Imprime PGG, Pembrolizumab - Pathologic Stage III Cutaneous Melanoma AJCC v8 | Phase 2 | Withdrawn | HiberCell, Inc. | 2021-08-15 | 2021-11-05 | |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) Regorafenib, Atezolizumab, Imprime PGG - Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 96 | 2018-09-27 | 2023-11-07 |
| Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD Imprime PGG, Pembrolizumab - Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Terminated | HiberCell, Inc. | 1 | 2017-11-08 | 2018-12-14 |
| Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 Imprime PGG, MK-3475 - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Lawrence Feldman, MD | 35 | 2017-07-11 | 2026-01-20 |
| Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer Imprime PGG, Pembrolizumab - Advanced Melanoma, Triple-Negative Breast Cancer | Phase 2 | Completed | HiberCell, Inc. | 64 | 2017-02-22 | 2024-07-09 |
| A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma Imprime PGG, Rituximab - Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas | Phase 2 | Completed | Dana-Farber Cancer Institute | 25 | 2014-12-01 | 2026-04-06 |
| (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer BTH1704, IMPRIME PGG, Gemcitabine - Pancreatic Cancer | Phase 1 | Terminated | University of Illinois at Chicago | 3 | 2014-08-01 | 2015-05-01 |
| Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Imprime PGG + cetuximab, Cetuximab - Colorectal Cancer | Phase 3 | Terminated | HiberCell, Inc. | 217 | 2011-04-01 | 2017-07-13 |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia alemtuzumab, rituximab, PGG beta-glucan - B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2011-01-01 | 2020-06-23 |
| Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer Imprime PGG - Colorectal Cancer | Completed | HiberCell, Inc. | 18 | 2009-06-01 | 2012-02-15 | |
| Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGG™ Injection Imprime PGG - Healthy | Phase 1 | Completed | HiberCell, Inc. | 24 | 2005-12-01 | 2007-10-11 |
Colorectal Neoplasms (3) · Recurrence (3) · Anophthalmia with pulmonary hypoplasia (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Melanoma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
HiberCell, Inc. (8) · Dana-Farber Cancer Institute (1) · Hoffmann-La Roche (1) · Lawrence Feldman, MD (1) · Mayo Clinic (1) · University of Illinois at Chicago (1)
United States (12) · France (2) · Australia (1) · Germany (1) · Puerto Rico (1) · South Korea (1) · Switzerland (1)
Alison Stopeck, MD (1) · Caron Jacobson, MD (1) · Jeremy D Graff, PhD (1) · Lawrence Feldman, M.D. (1) · Leonard Saltz, MD (1) · Mark O'Hara (1) · Neeta Venepalli, MD (1) · Neil H. Segal, MD, PhD (1) · Neil Senzer, MD (1) · Purvi Gada, MD (1) · Steven Ansell, M.D. (1)
2017 (1)